Brief: Sichuan Kelun-Biotech Biopharmaceutical Updates On Sacituzumab Tirumotecan
31/10/2024 01:26
Oct 31 (Reuters) - Sichuan Kelun-Biotech
Biopharmaceutical Co Ltd 6990.HK :
* NEW DRUG APPLICATION FOR CORE PRODUCT SACITUZUMAB
TIRUMOTECAN
(SAC-TMT) ACCEPTED BY NMPA
Further company coverage: 6990.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sichuan Kelun-Biotech Biopharmaceutical
See all newsBrief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes To CZB Structured Deposit VI For RMB500 Mln
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT
Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable Of RMB 388 MLN